# Epithalon: Twenty-Five Years of Telomerase and Pineal-Gland Research

> Epithalon — the synthetic tetrapeptide Ala-Glu-Asp-Gly — has activated telomerase, extended telomeres in human cell lines, and normalized melatonin circadian rhythm across two decades of research from the St. Petersburg Institute and beyond.

A naturalist's reading room for the Ala-Glu-Asp-Gly tetrapeptide literature — from Khavinson's first telomerase findings in 2003 to the 2025 Western confirmations, every quantitative claim cited to its source.

## What Is Epitalon Peptide?

Epithalon is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG) and a molecular weight of approximately 390 Da [17]. It was derived from the active fraction of Epithalamin — a crude polypeptide extract of bovine pineal glands studied at the St. Petersburg Institute of Bioregulation and Gerontology since the 1970s. The synthetic version allows precise dosing and purity control not possible with the bovine extract. Its presence in human pineal tissue has been confirmed as of 2017 [17].

The compound belongs to a class called bioregulator peptides — short sequences of two to four amino acids designed by Khavinson's group to selectively modulate organ-specific gene expression. Epithalon is the pineal bioregulator: it is studied primarily for its effects on telomerase activity, telomere length, and circadian neuroendocrine rhythm in aged cells and organisms.

Both spellings — Epithalon and Epitalon — refer to the identical molecule. The alternate spelling arises from transliteration conventions between Russian and English scientific literature. Both appear in PubMed-indexed publications; both are used on this site.

## What Is Epitalon Peptide Used For in Research?

Research applications for Epithalon (Epitalon) span five documented areas: telomere biology, longevity and aging-biomarker studies, circadian rhythm normalization, oncostatic effect in tumor models, and neuroprotection in retinal and neurogenic studies.

The telomere work is the most reproduced: Khavinson and colleagues demonstrated hTERT gene reactivation and telomere elongation in human fetal fibroblasts in 2003 [1], and a 2025 study from Brunel University (Al-dulaimi et al.) confirmed dose-dependent telomere lengthening across four human cell lines at 0.1–1.0 μg/mL [2]. That 2025 paper is the first major Western-institution replication and represents the clearest independent confirmation of the central telomere claim.

The longevity data comes primarily from rodent models. In female SHR mice, monthly subcutaneous Epitalon at 1.0 μg/mouse extended maximum lifespan by 12.3% and reduced chromosome aberrations in bone marrow by 17.1% [4]. In Drosophila melanogaster, Epitalon at extremely low larval dietary concentrations — 0.001 to 5 × 10⁻⁶ wt.% — extended lifespan by 11–16% [3]. The circadian work involves melatonin: Epitalon restored evening melatonin synthesis in senescent rhesus macaques [5] and normalized the circadian rhythm of cortisol secretion. In elderly human subjects with pineal insufficiency, it increased nighttime melatonin concentrations in a bidirectional, modulatory fashion rather than simply stimulating production [6].

Oncostatic effects have been observed in HER-2/neu transgenic mice (mammary tumor suppression) [9] and in chemically induced colon carcinogenesis models [10]. The 2025 comprehensive review by Araj et al. summarizes twenty-five years of findings across these domains and notes that the precise unified mechanism remains under investigation [17].

## Epithalon Longevity Research

The lifespan evidence for Epithalon is real, reproducible across species, and honest about its limits. In Drosophila, dietary Epitalon at larval stage extended lifespan 11–16%, with sex-dependent optimal dose differences [3]. In two separate mouse cohorts — SHR mice and senescence-accelerated SAMP-1 mice — monthly subcutaneous protocols extended the survival of late-cohort individuals (the last 10% of survivors) by 12.3–13.3% [4, 14]. The parent compound Epithalamin extended mean lifespan 25% in rats in earlier Khavinson-group studies [17].

The limitation is equally clear: nearly all longevity evidence originates from one research group (Khavinson and Anisimov at the St. Petersburg Institute of Bioregulation and Gerontology). No independent rodent lifespan replication exists from a separate laboratory, and no randomized controlled trial in humans has been conducted for longevity endpoints. The 2025 Western confirmation by Al-dulaimi et al. addressed telomere elongation in cell lines — not lifespan — and found the telomere effect real at 0.1–1.0 μg/mL [2]. That is meaningful corroboration of the central mechanistic claim without being a full lifespan study.

Human longevity data is absent. The compound has no published randomized trial in humans for any aging endpoint. The honest reading: Epithalon has accumulated a reproducible preclinical record in invertebrates and rodents, a mechanistically credible cell-line record confirmed independently in 2025, and an observational human record in melatonin normalization and retinitis pigmentosa — but the human lifespan claim remains a projection from the animal data, not a demonstrated outcome.

## What Are the Benefits of Epithalon in Research?

Across the published literature, five categories of effects have been studied: telomerase activation and telomere elongation [1, 2], antioxidant gene upregulation via the Nrf2/Keap1 pathway (SOD2, CAT, HMOX1) [15], melatonin circadian normalization via pineal AANAT/pCREB modulation [5, 6, 7], oncostatic effects in rodent tumor models [9, 10, 16], and neurogenic gene upregulation in mesenchymal stem cells [11, 12].

The 2025 overview by Araj et al. consolidates these: telomere elongation averaging 33.3% in human lymphocytes, 16% lifespan extension in Drosophila, 43.9% prolonged retinal function in Campbell rats, and a 16-fold increase in telomerase activity in normal mammary epithelial cells [17]. These are preclinical figures. They document what was measured in laboratory conditions; they do not translate directly to human therapeutic outcomes.

Antioxidant findings add a parallel mechanistic strand. In hyperglycemic retinal epithelial cells (ARPE-19), Epitalon at 20–60 ng/mL restored expression of SOD2, CAT, and HMOX1 — antioxidant genes suppressed by high-glucose stress — and recovered impaired wound healing by inhibiting EMT transcription factors SNAIL-1, ZEB-1, and TWIST1 [15]. That 2025 study (Gatta et al.) adds a new mechanistic layer beyond telomere biology: epigenetic protection against hyperglycemia-induced DNA hypomethylation.

For each of these benefits, the evidence is preclinical or observational. The [telomerase activation mechanism](/research#telomerase) and [pineal gland regulatory effects](/research#pineal-gland) are documented in detail on the research page.

## Epitalon: The Alternate Spelling

Epitalon and Epithalon are the same molecule. The sequence Ala-Glu-Asp-Gly is identical regardless of which transliteration convention appears in the source text. 'Epitalon' is the form used in Russian scientific publications and in much of the early PubMed-indexed literature (Khavinson 2000, 2001, 2002, 2003). 'Epithalon' is the variant that has gained traction in English-language commercial and some academic contexts, and it carries higher tracked English-language search volume.

This site uses both spellings. Primary keyword placement follows the higher-volume English form, Epithalon. Body copy uses Epitalon wherever a Russian-literature citation uses that form, because that is what the cited paper says. No transliteration choice changes the compound's chemistry, mechanism, or research record.

See the [Epitalon vs. Epithalon spelling](/#epitalon-vs-epithalon) note above. For the broader definitional distinction between the natural extract and the synthetic peptide, see the [Epithalamin vs. Epithalon section](/research#epithalamin) on the research page.

---

Gilt scrollwork around a twenty-five year literature — the Epithalon record read leaf by leaf, cited to the source, and held by no clinic and no vendor.